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fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents ofthe Proceedings can be found at the back of
this issue.

Vitamin D metabolities: New physiologic and clinical
insights. M.R. Haussler, S. D o k o h , D.J. Mangelsdorf, C A .
Donaldson, and J.W. Pike (68)

W i t h t h e availability of stereospecific assays for vitamin
D and its metabolites, many clinicians now measure
these sterols in evaluating the pathogenesis and treatment of diseases affecting mineral and skeletal homeostasis. Since some of these assays are commercially available, it seems appropriate to reflect on what they
measure and how to interpret the results. M u c h new
information published over the past 10-12 years can be
confusing. Other sections of this Symposium dealt specifically with certain diseases affecting vitamin D metabolism, but Haussler, Stanbury, DeLuca, and Rasmussen
dealt directly with the biological relevance of sterol prod u c t i o n , quantitation, and the interpretation of the
sterol assay data in light o f t h e presumed activities of the
vitamin's metabolites.

one of carrier-mediation into tissues, it seems likely that
estimates of " f r e e " sterol could be useful in situations in
which sterol transport is either compromised or augmented by changes in the protein's concentration and/or
its occupancy by sterols.

Vitamin D metabolism in man: Contributions from clinical studies. S.W. Stanbury and E.B. Mawer (72)
The cardinal role of1,25-dihydroxyvitamin D y n mineral
homeostasis. H.F. DeLuca (78)
The role of 1,25{OH)yD^ in the pathogenesis of osteomalacia. H. Rasmussen (82)

Two controversial areas in the interpretation of sterol
values are the role(s) of sterols other than 1,25-(OH)2D
and the relevance of the extrarenal production of 1,25(OH)2D. These areas were directly addressed in this section. The emphasis of Stanbury and Mawer (pp. 72 ff.) on
1,25-(OH)2D underscored the view that this sterol is the
cardinal metabolite in the expression of the vitamin's
" t r a d i t i o n a l " biological activity. The clear-cut alliances of
several relevant diseases with 1,25-(OH)2D underproduction, overproduction, and resistance support this position. Extrarenal 1,25-(OH)2D synthesis currently appears
to be clinically significant in sarcoidosis and certainly of
interest in pregnancy, but as DeLuca (pp. 78 ff.) indicated,
of uncertain in vivo significance in other tissues.

As indicated by Haussler and colleagues (pp. 68 ff.), the
competitive protein binding assays (CPBA) have had the
greatest usage, but we must be aware of the improved
technology suggested by the novel cytoreceptor assay
(1), polyclonal radioimmunoassay (RIA) (2), monoclonal
RIA (3), and innovative, facile preparative approaches to
CPBA (4). Continuing progress in the development of
selective, sensitive, precise, convenient assays seems
likely. Although available, quantitation of the vitamin D
carrier protein (DBP) has not gained wide usage in the
interpretation of " b o u n d " or " f r e e " sterol (5). I f t h e role
of DBP in blood sterol transport is indeed passive and not

Rasmussen (pp. 82 ff.) provided a broad view of sterol
action and addressed the controversial areas dealing with
the role of other sterols in mineral and skeletal homeosta-
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tis. in contrast to Rasmussen's contention, DeLuca indicated that the introduction of a fluoro group at position
C-25 markedly reduced biological activity, but that a
fluoro group at C-24 did not reduce biological effects.

interpreting sterol assay values. Nutritional or p h o t o b i o logical, hormonal, and possibly ionic and autoregulatory
influences can condition blood sterol concentration.
Recent studies of the clearance of sterol(s) f r o m blood
suggest that alterations in sterol degradation might characterize certain conditions, such as the augmented loss
of water-soluble sterol conjugates into the urine of
patients with cholestatic liver disease (9).

The concept of both renal and extrarenal biosynthesis of
1,25-(OH)2D has withstood challenges far better than
hypotheses of new target tissues for this potent sterol.
Many reports have convincingly demonstrated the presence of high affinity, selective 1,25-(OH)2D receptors in
tissues not usually associated with major translocations
of mineral ions (6). This latter review also suggested a
role for 24,25-(OH)2D in various activities, but Haussler
and co-workers revealed their present inability to c o n firm these findings. An exciting development by Pike (7)
is the production of monoclonal antibodies to the 1,25(OH)2D receptor, which provides a new probe to reveal
the topography and relevance of the sterol-receptor
association. The influence of 1,25-(OH)2D on cellular
differentiation, whether calcium-mediated or not, will
clearly attract future investigators.

The relationships among 1,25-(OH)2D and substrate sterol,
ions, and hormones addressed by Stanbury and Mawer
underscored their importance in the interpretation of
single and perturbed plasma 1,25-(OH)2D levels. Provocative testing of 25-OHD-1a-hydroxylase activity will
clearly be an active area for future workers (10).
A major clinical focus for the controversy surrounding
the importance of 1,25-(OH)2D is the observation that
osteomalacia can develop in the presence of slightly
high, normal, or low blood concentrations of this sterol.
Several factors are relevant: substrate (25-OHD) availability, dietary mineral content, age of the patient or rate
of g r o w t h , degree of secondary hyperparathyroidism,
renal function. In other words, normal 1,25-(OH)2D
blood levels may be inappropriately low in a situation
demanding very high levels in order to provide sufficient
intestinal mineral transportfor mineralization of theskeleton. The observation that 1,25-(OH)2D blood levels are
five to six times higher during the healing of vitamin
D-deficient osteomalacia suggests the possibility of a
non-PTH, la-hydroxylase-stimulator of skeletal origin.

The influencesof 1,25-(OH)2Don cellulardifferentiation
provide some basis to broaden our viewpoints about the
action(s) and target tissues for vitamin D. This area, in
relationship to myelogenous leukemia cells, has recently
been reviewed (8). Further work may be expected in the
delineation of sterol effects on cells not classically associated with bulk transfer of minerals.
Interesting clinical observations by Stanbury and Mawer
suggested the importance of several factors in carefully
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